Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication November 25, 2011
- Accepted for publication May 31, 2012
- Published online November 1, 2012.
Article Versions
- previous version (October 10, 2012 - 05:24).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2012 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Annette Altmann1,2,
- Annette Markert1,2,
- Vasileios Askoxylakis3,
- Tilman Schöning4,
- Ralf Jesenofsky5,
- Michael Eisenhut6 and
- Uwe Haberkorn1,2
- 1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
- 2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ) and University Hospital Heidelberg, Heidelberg, Germany
- 3Department of Radiooncology, University Hospital Heidelberg, Heidelberg, Germany
- 4Department of Pharmacy, University Hospital Heidelberg, Heidelberg, Germany
- 5Department of Medicine II, Medical Faculty of Mannheim, Mannheim, Germany; and
- 6Department of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany
- For correspondence or reprints contact: Annette Altmann, Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail: a.altmann{at}dkfz.de
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- The ERK1/2-Elk1, JNK-cJun, and JAK-STAT Transcriptional Axes as Potential Bortezomib Resistance Mediators in Prostate Cancer
- Investigating the mechanisms underlying Bortezomib resistance
- RhoB upregulation leads to either apoptosis or cytostasis through differential target selection
- Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer